Captrust Financial Advisors purchased a new stake in shares of Celgene Corporation (NASDAQ:CELG) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 5,802 shares of the biopharmaceutical company’s stock, valued at approximately $754,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. State Street Corp grew its holdings in Celgene Corporation by 2.3% during the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after buying an additional 723,844 shares in the last quarter. Jennison Associates LLC boosted its holdings in shares of Celgene Corporation by 1.2% in the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock worth $1,742,301,000 after purchasing an additional 156,864 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Celgene Corporation by 3.3% in the 2nd quarter. Franklin Resources Inc. now owns 11,080,093 shares of the biopharmaceutical company’s stock worth $1,439,025,000 after purchasing an additional 349,974 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Celgene Corporation by 3.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 9,874,214 shares of the biopharmaceutical company’s stock worth $1,282,369,000 after purchasing an additional 342,580 shares during the period. Finally, Pioneer Investment Management Inc. boosted its holdings in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock worth $650,911,000 after purchasing an additional 710,584 shares during the period. Institutional investors and hedge funds own 79.16% of the company’s stock.

CELG has been the subject of a number of recent research reports. Vetr cut Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $146.88 target price for the company. in a report on Tuesday, August 29th. Royal Bank Of Canada dropped their target price on Celgene Corporation from $166.00 to $148.00 and set a “top pick” rating for the company in a report on Friday, October 27th. Leerink Swann reiterated a “buy” rating and issued a $156.00 target price on shares of Celgene Corporation in a report on Friday, October 20th. Morgan Stanley dropped their target price on Celgene Corporation from $120.00 to $115.00 and set an “underweight” rating for the company in a report on Monday, October 23rd. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $139.87.

Celgene Corporation (CELG) opened at $104.10 on Friday. The company has a market capitalization of $81,959.70, a price-to-earnings ratio of 16.27, a PEG ratio of 0.80 and a beta of 1.79. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The business’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. research analysts anticipate that Celgene Corporation will post 6.67 earnings per share for the current year.

In related news, insider Terrie Curran sold 1,727 shares of the business’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Michael D. Casey sold 9,250 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now owns 9,250 shares in the company, valued at $1,286,027.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 20,227 shares of company stock valued at $2,843,956. Corporate insiders own 0.95% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.dailypolitical.com/2017/11/19/captrust-financial-advisors-purchases-new-holdings-in-celgene-corporation-celg.html.

About Celgene Corporation

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.